Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)

被引：41

作者：

Apostolidis, Leonidas ^{[1
]}

Dal Buono, Arianna ^{[2
,4
]}

Merola, Elettra ^{[2
,5
]}

Jann, Henning ^{[2
]}

Jaeger, Dirk ^{[1
]}

Wiedenmann, Bertram ^{[2
]}

Winkler, Eva Caroline ^{[1
]}

Pavel, Marianne ^{[2
,3
]}

机构：

[1] Heidelberg Univ Hosp, Natl Ctr Tumor Dis NCT Heidelberg, Dept Med Oncol, D-69120 Heidelberg, Germany

[2] Charite, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany

[3] Friedrich Alexander Univ Erlangen Nuremberg, Dept Med 1, Div Endocrinol, D-91054 Erlangen, Germany

[4] Humanitas Clin & Res Ctr IRCCS, Digest Endoscopy Unit, Dept Gastroenterol, I-20089 Milan, Italy

[5] Azienda Prov & Serv Sanit APSS, Santa Chiara Hosp, Dept Gastroenterol, I-38079 Trento, Italy

来源：

CANCERS | 2021年 / 13卷 / 08期

关键词：

NET G3; neuroendocrine tumor; neuroendocrine carcinoma; systemic therapy; chemotherapy; peptide receptor radionuclide therapy; first-line; RECEPTOR RADIONUCLIDE THERAPY; CHEMOTHERAPY; EVEROLIMUS; CARCINOMAS; NEOPLASMS; CELL; STREPTOZOCIN; CAPECITABINE; FLUOROURACIL; TEMOZOLOMIDE;

D O I：

10.3390/cancers13081936

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Neuroendocrine tumors grade 3 (NET G3) are a newly defined subgroup of neuroendocrine neoplasms. They do not respond well to platinum + etoposide-based chemotherapy. The alternative suggested options have not been analyzed in untreated NET G3 patients so far, therefore the optimal treatment strategy for these tumors is unclear. In our analysis we showed that FOLFOX is the most active regimen holding the highest chance of tumor shrinkage, whereas temozolomide/capecitabine is the most effective, leading to the most durable tumor control. Well-differentiated grade 3 neuroendocrine tumors (NET G3) have been distinguished from poorly differentiated neuroendocrine carcinomas (NEC) in the most current WHO classifications. Commonly applied first-line chemotherapy protocols with cisplatin or carboplatin in combination with etoposide (PE) are less effective in NET G3 than NEC. Suggested alternative treatment protocols have not been studied in first-line therapy of NET G3 so far. We performed a retrospective analysis of patients with NET G3 in the databases of 3 German cancer centers. Out of 142 patients, 136 patients received palliative first-line therapy: overall response rate (ORR) was 35.1% for PE (n = 37), 56.4% for FOLFOX (n = 39), 27.3% for temozolomide/capecitabine (TEM/CAP) (n = 22), 45.0% for streptozotocin/5-fluorouracil (STZ/5-FU) (n = 20), and 16.7% for other (n = 18). Median progression-free survival (PFS) for PE was 6.9 months. Compared to PE, PFS in the other treatment groups was 6.9 months for FOLFOX (p = 0.333), 12.0 months for TEM/CAP (p = 0.093), 4.8 months for STZ/5-FU (p = 0.919), and 14.1 months for other (p = 0.014). In a univariate setting, all non-PE patients combined showed a significantly prolonged PFS vs. PE (9.0 months; p = 0.049) which could not be confirmed in a multivariate analysis. In conclusion, NET G3 with FOLFOX showed the highest ORR, and with TEM/CAP showed the longest PFS. Further prospective evaluation of the optimal therapeutic strategy for this tumor entity is needed.

引用

页数：14

共 36 条

[1]

Bosman F. T., 2010, WHO classification of tumours of the digestive system

[2] Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study [J].

Carlsen, Esben Andreas ;

Fazio, Nicola ;

Granberg, Dan ;

Grozinsky-Glasberg, Simona ;

Ahmadzadehfar, Hojjat ;

Grana, Chiara Maria ;

Zandee, Wouter T. ;

Cwikla, Jaroslaw ;

Walter, Martin A. ;

Oturai, Peter Sandor ;

Rinke, Anja ;

Weaver, Andrew ;

Frilling, Andrea ;

Gritti, Sara ;

Arveschoug, Anne Kirstine ;

Meirovitz, Amichay ;

Knigge, Ulrich ;

Sorbye, Halfdan .

[3] Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms [J].

Chatzellis, Eleftherios ;

Angelousi, Anna ;

Daskalakis, Kosmas ;

Tsoli, Marina ;

Alexandraki, Krystallenia I. ;

Wachula, Ewa ;

Meirovitz, Amichay ;

Maimon, Ofra ;

Grozinsky-Glasberg, Simona ;

Gross, David ;

Kos-Kudla, Beata ;

Koumarianou, Anna ;

Kaltsas, Gregory .

NEUROENDOCRINOLOGY, 2019, 109 (04) :333-345

[4] Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor [J].

de Mestier, Louis ;

Walter, Thomas ;

Evrard, Camille ;

de Boissieu, Paul ;

Hentic, Olivia ;

Cros, Jerome ;

Tougeron, David ;

Lombard-Bohas, Catherine ;

Rebours, Vinciane ;

Hammel, Pascal ;

Ruszniewski, Philippe .

NEUROENDOCRINOLOGY, 2020, 110 (1-2) :83-91

[5] A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations [J].

Elvebakken, Hege ;

Perren, Aurel ;

Scoazec, Jean-Yves ;

Tang, Laura H. ;

Federspiel, Birgitte ;

Klimstra, David S. ;

Vestermark, Lene W. ;

Ali, Abir S. ;

Zlobec, Inti ;

Myklebust, Tor A. ;

Hjortland, Geir O. ;

Langer, Seppo W. ;

Gronbaek, Henning ;

Knigge, Ulrich ;

Tiensuu Janson, Eva ;

Sorbye, Halfdan .

NEUROENDOCRINOLOGY, 2021, 111 (09) :883-894

[6] ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas [J].

Garcia-Carbonero, R. ;

Sorbye, H. ;

Baudin, E. ;

Raymond, E. ;

Wiedenmann, B. ;

Niederle, B. ;

Sedlackova, E. ;

Toumpanakis, C. ;

Anlauf, M. ;

Cwikla, J. B. ;

Caplin, M. ;

O'Toole, D. ;

Perren, A. .

NEUROENDOCRINOLOGY, 2016, 103 (02) :186-194

[7] Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma [J].

Hadoux, J. ;

Malka, D. ;

Planchard, D. ;

Scoazec, J. Y. ;

Caramella, C. ;

Guigay, J. ;

Boige, V. ;

Leboulleux, S. ;

Burtin, P. ;

Berdelou, A. ;

Loriot, Y. ;

Duvillard, P. ;

Chougnet, C. N. ;

Deandreis, D. ;

Schlumberger, M. ;

Borget, I. ;

Ducreux, M. ;

Baudin, E. .

[8] Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms [J].

Heetfeld, M. ;

Chougnet, C. N. ;

Olsen, I. H. ;

Rinke, A. ;

Borbath, I. ;

Crespo, G. ;

Barriuso, J. ;

Pavel, M. ;

O'Toole, D. ;

Walter, T. .

[9] FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3 [J].

Hentic, O. ;

Hammel, P. ;

Couvelard, A. ;

Rebours, V. ;

Zappa, M. ;

Palazzo, M. ;

Maire, F. ;

Goujon, G. ;

Gillet, A. ;

Levy, P. ;

Ruszniewski, P. .

[10] Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers [J].

Klein, Oliver ;

Kee, Damien ;

Markman, Ben ;

Michael, Michael ;

Underhill, Craig ;

Carlino, Matteo S. ;

Jackett, Louise ;

Lum, Caroline ;

Scott, Clare ;

Nagrial, Adnan ;

Behren, Andreas ;

So, Jane Y. ;

Palmer, Jodie ;

Cebon, Jonathan .

CLINICAL CANCER RESEARCH, 2020, 26 (17) :4454-4459

← 1 2 3 4 →